Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of cerliponase alfa in CLN2 disease
2014-003480-37Phase 2Unknown
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Oct 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cerliponase alfa in neuronal ceroid lipofuscinosis type 2 (CLN2) and neuronal ceroid lipofuscinoses (NCL), sponsored by BioMarin Pharmaceutical Inc. Primary endpoints: Long-term efficacy and Long-term safety. Status: unknown.
02
Drugs
cerliponase alfa
03
Conditions
neuronal ceroid lipofuscinosis type 2 (CLN2)neuronal ceroid lipofuscinoses (NCL)
Beyond the preview
Go deeper on 2014-003480-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003480-37.